The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).
Alexander E. Perl
No relevant relationships to disclose
Hartmut Dohner
Consultant or Advisory Role - Ambit BioSciences
Philippe H. Rousselot
No relevant relationships to disclose
Jean-Pierre Marie
Other Remuneration - Ambit BioSciences
Giovanni Martinelli
No relevant relationships to disclose
Neil P. Shah
No relevant relationships to disclose
Mark J. Levis
Consultant or Advisory Role - Astellas Pharma
Guy Gammon
Employment or Leadership Position - Ambit BioSciences
Stock Ownership - Ambit BioSciences
Denise Trone
Employment or Leadership Position - Ambit BioSciences
Jorge E. Cortes
Consultant or Advisory Role - Novartis